安徽黄山胶囊股份有限公司 关于公司高管减持股份计划实施完毕的公告 公司高管叶松林先生保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 安徽黄山胶囊股份有限公司（以下简称"公司"）于 2025 年 5 月 30 日披露 了《关于公司高管减持股份的预披露公告》（公告编号：2025-016），公司高管叶 松林先生计划自前述公告披露之日起 15 个交易日后的 3 个月内以集中竞价交易 方式减持公司股份 430,000 股（占公司总股本比例 0.1438%）。 证券代码：002817 证券简称：黄山胶囊 公告编号：2025-017 | 股东名称 | 股份性质 | | 本次减持前持有股份 | | 本次减持后持有股份 | | --- | --- | --- | --- | --- | --- | | | | 股数（股） | 占总股 | 股数（股） | 占总股 | | | | | 本比例（%） | | 本比例（%） | | 叶松林 | 合计持有股份 | 1,725,500 | 0.5769 | 1,295,500 | 0. ...

Core Viewpoint - Huangshan Capsule's stock closed at 7.23 yuan on June 24, with a 2.55% increase, resulting in a rolling PE ratio of 40.98 times and a total market value of 2.162 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In the first quarter of 2025, the company reported an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% with a sales gross margin of 29.26% [2] - The company's PE ratio (TTM) stands at 40.98, while the industry average is 49.12, and the industry median is 36.07 [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the medical device industry average PE at 49.12 and the median at 36.07 [1][2] - The company has received several accolades, including the "Anhui Famous Brand Product" for its "Jingchuan" brand gelatin hollow capsules and recognition as an excellent product brand in the pharmaceutical excipients sector [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.41 yuan, up 1.51%, with a rolling PE ratio of 42.00, marking a new low in 325 days, and a total market value of 2.216 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the industry based on PE ratio, with the average PE ratio for the medical device industry at 50.64 and the median at 37.05 [2] - The average market value of the industry is 10.91 billion yuan, while Huangshan Capsule's market value is 2.216 billion yuan [2] Shareholder Information - As of March 31, 2025, Huangshan Capsule had 18,378 shareholders, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-016 安徽黄山胶囊股份有限公司 关于公司高管减持股份的预披露公告 公司高管叶松林先生保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 公司高管叶松林先生持有公司股份 1,725,500 股（占公司总股本比例 0.5769%），计划在公告之日起 15 个交易日后的 3 个月内以集中竞价交易方式 减持公司股份 430,000 股（占公司总股本比例 0.1438%）。 一、股东基本情况 1、股东名称：叶松林 2、股东持有股份的总数量、占公司总股本的比例： 截至本公告披露日，叶松林先生持有公司股份 1,725,500 股，占本公司总股 本比例 0.5769%。 二、本次减持计划的主要内容 1、本次拟减持的原因：个人资金需求； 2、股份来源：公司首次公开发行前持有股份及资本公积金转增股份； 3、拟减持股份数量及比例：拟减持股份数量 430,000 股，占公司总股本的 0.1438%。若减持计划实施期间如遇派息、送股、资本公积金转增股本、配股 ...

Group 1 - The company announced that its executive, Mr. Ye Songlin, plans to reduce his shareholding by 430,000 shares, which represents 0.1438% of the company's total share capital [1]

Core Viewpoint - Huangshan Capsule's stock closed at 7.21 yuan, up 1.12%, with a rolling PE ratio of 40.87, marking a new low in 103 days, and a total market value of 2.156 billion yuan [1][2] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - In Q1 2025, the company achieved an operating income of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year, with a gross profit margin of 29.26% [2] Market Position - Huangshan Capsule ranks 84th in the medical device industry based on PE ratio, with the industry average at 49.51 and the median at 36.17 [1][2] - The average PE ratio for the industry is significantly higher than Huangshan Capsule's current PE ratio, indicating potential undervaluation [2]

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-015 安徽黄山胶囊股份有限公司 2024 年度分红派息实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、股东大会审议通过利润分配方案的情况 1. 安徽黄山胶囊股份有限公司（以下简称"公司"或"本公司"）于 2025 年 4 月 25 日召开 2024 年度股东大会，审议通过《关于公司 2024 年度利润分配 预案的议案》，具体内容如下： 以公司现有总股本 299,098,170 股为基数，向全体股东每 10 股派发现金红 利人民币 0.38 元（含税），合计派发现金红利人民币 11,365,730.46 元（含税）； 2. 自分配方案披露至实施期间公司股本总额未发生变化，若本次分配方案 披露至实施期间，公司总股本发生变化，将按照分配总额固定的原则实施； 本公司 2024 年度权益分派方案为：以公司现有总股本 299,098,170 股为基 数，向全体股东每 10 股派 0.380000 元人民币现金（含税；扣税后，通过深股通 持有股份的香港市场投资者、境外机构（含 QFII、RQF ...

Core Viewpoint - Huangshan Capsule's stock closed at 6.77 yuan, up 1.50%, with a rolling PE ratio of 38.38, marking a new low in 18 days, and a total market value of 2.025 billion yuan [1] Company Overview - Anhui Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] - The company's trademark is rated as a famous trademark in Anhui Province, and its "Jingchuan" brand products have received various accolades, including "Anhui Famous Brand Product" [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin stood at 29.26% [2] Market Position - Huangshan Capsule's PE ratio of 38.38 is below the industry average of 47.74 and the industry median of 36.15, ranking 80th in the industry [2] - The company has two institutional investors holding a total of 91.2068 million shares, with a combined market value of 594 million yuan [1]

Core Viewpoint - Huangshan Capsule achieved unexpected growth in Q1 2025, with revenue of 119.04 million yuan, a slight increase of 0.53% year-on-year, and a net profit of 18.84 million yuan, up 22.90% year-on-year, reflecting the effectiveness of its high-end transformation strategy and changes in the competitive landscape of the industry [1] Group 1: Financial Performance - In Q1 2025, the company reported a net profit of 18.84 million yuan, a year-on-year increase of 22.90%, and a non-net profit of 18.20 million yuan, up 27.65% year-on-year [1] - The overall gross margin increased by 4.5 percentage points to 29.26% year-on-year, indicating successful structural transformation of its product lines [2] - The net profit margin rose to 15.94%, higher than the industry average, supported by effective cost control, with the ratio of expenses to revenue decreasing to 8.75% [2] Group 2: Product Development and Market Strategy - The demand for traditional gelatin capsules is slowing, while high-end products like enteric capsules and plant-based capsules are experiencing significant growth, with the latter achieving a revenue increase of 64.37% [2] - The company has developed a full product matrix including gelatin capsules, enteric capsules, and HPMC capsules, enhancing its competitive edge [1] - The "technology-driven" strategy has entered a harvest phase, with digital transformation improving operational efficiency and new product technologies being developed [3] Group 3: Operational Efficiency and Global Expansion - The asset-liability ratio decreased to 15.09%, significantly lower than the industry average of 28%, providing a safety net for R&D investments [3] - The company is actively pursuing global expansion, with overseas revenue contributing 16.82%, an increase of 3.2 percentage points from 2023, indicating the initial success of its international strategy [3] - The dual strategy of "high-end and globalization" has proven effective, allowing the company to navigate challenges in the industry and providing a replicable model for transformation [3]